Data-driven analysis of technological biomarkers and functional myocardial ischemia in stable coronary artery disease using advanced statistical modeling.

IF 1.8 4区医学 Q4 ENGINEERING, BIOMEDICAL

Technology and Health Care Pub Date : 2025-09-01 Epub Date: 2025-04-29 DOI:10.1177/09287329251333873

Cheng Cheng, Yan Li, Yifang Huang, Bei Du

{"title":"Data-driven analysis of technological biomarkers and functional myocardial ischemia in stable coronary artery disease using advanced statistical modeling.","authors":"Cheng Cheng, Yan Li, Yifang Huang, Bei Du","doi":"10.1177/09287329251333873","DOIUrl":null,"url":null,"abstract":"Background: Functional myocardial ischemia (FMI) in stable coronary artery disease (SCAD) remains a critical challenge in cardiovascular care. While fractional flow reserve (FFR) is a gold-standard diagnostic technology, its clinical adoption is limited by cost and complexity. Integrating technological biomarkers and advanced analytics could enhance risk stratification and guide precision interventions.Objective: This study leverages data-driven methodologies to identify and validate technological biomarkers associated with FMI in SCAD, aiming to optimize clinical decision-making through predictive modeling.Methods: A systematic search across PubMed, Embase, and Web of Science (inception-October 2023) identified studies evaluating SCAD and FMI.Inclusion criteria: cohort/case-control studies (n ≥ 100) using FFR or angiographic technologies. Meta-analyses were conducted via RevMan 5.4 and Stata 16.0, employing fixed/random-effects models. Heterogeneity was assessed using I² statistics.Results: Analysis of 15 studies (n = 4854) revealed that anatomical biomarkers-stenosis severity (DS%: SMD = 0.95, p < 0.0001), minimal lumen diameter (SMD = -1.33, p < 0.0001), and lesion length (SMD = 0.72, p < 0.0001)-were strongly linked to FMI. Diabetes (OR = 1.31, p = 0.003) and smoking (OR = 1.47, p < 0.0001) emerged as significant modifiable risks, while hypertension showed no association (p = 0.14). Age and gender disparities highlighted the need for personalized risk algorithms.Conclusion: Technological biomarkers and data-driven modeling provide actionable insights into FMI risk in SCAD, bridging gaps between anatomical assessments and functional outcomes. Future integration of machine learning and predictive analytics could refine risk stratification, enabling tailored therapeutic strategies.","PeriodicalId":48978,"journal":{"name":"Technology and Health Care","volume":" ","pages":"2164-2176"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology and Health Care","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/09287329251333873","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Functional myocardial ischemia (FMI) in stable coronary artery disease (SCAD) remains a critical challenge in cardiovascular care. While fractional flow reserve (FFR) is a gold-standard diagnostic technology, its clinical adoption is limited by cost and complexity. Integrating technological biomarkers and advanced analytics could enhance risk stratification and guide precision interventions.

Objective: This study leverages data-driven methodologies to identify and validate technological biomarkers associated with FMI in SCAD, aiming to optimize clinical decision-making through predictive modeling.

Methods: A systematic search across PubMed, Embase, and Web of Science (inception-October 2023) identified studies evaluating SCAD and FMI.

Inclusion criteria: cohort/case-control studies (n ≥ 100) using FFR or angiographic technologies. Meta-analyses were conducted via RevMan 5.4 and Stata 16.0, employing fixed/random-effects models. Heterogeneity was assessed using I² statistics.

Results: Analysis of 15 studies (n = 4854) revealed that anatomical biomarkers-stenosis severity (DS%: SMD = 0.95, p < 0.0001), minimal lumen diameter (SMD = -1.33, p < 0.0001), and lesion length (SMD = 0.72, p < 0.0001)-were strongly linked to FMI. Diabetes (OR = 1.31, p = 0.003) and smoking (OR = 1.47, p < 0.0001) emerged as significant modifiable risks, while hypertension showed no association (p = 0.14). Age and gender disparities highlighted the need for personalized risk algorithms.

Conclusion: Technological biomarkers and data-driven modeling provide actionable insights into FMI risk in SCAD, bridging gaps between anatomical assessments and functional outcomes. Future integration of machine learning and predictive analytics could refine risk stratification, enabling tailored therapeutic strategies.

查看原文本刊更多论文

采用先进的统计模型对稳定型冠状动脉疾病的技术生物标志物和功能性心肌缺血进行数据驱动分析。

背景：稳定性冠状动脉疾病（SCAD）的功能性心肌缺血（FMI）仍然是心血管护理的一个关键挑战。虽然部分血流储备（FFR）是一种金标准诊断技术，但其临床应用受到成本和复杂性的限制。整合技术生物标志物和先进的分析可以增强风险分层和指导精确干预。目的本研究利用数据驱动的方法来识别和验证与SCAD FMI相关的技术生物标志物，旨在通过预测建模优化临床决策。方法系统检索PubMed， Embase和Web of Science（启动- 2023年10月），确定评估SCAD和FMI的研究。纳入标准：采用FFR或血管造影技术的队列/病例对照研究（n≥100）。meta分析采用RevMan 5.4和Stata 16.0进行，采用固定/随机效应模型。采用I²统计量评估异质性。结果15项研究（n = 4854）的解剖生物标志物-狭窄严重程度（DS%: SMD = 0.95, p p p = 0.003）和吸烟（OR = 1.47, p p = 0.14）。年龄和性别差异突出了个性化风险算法的必要性。技术生物标志物和数据驱动建模为SCAD FMI风险提供了可行的见解，弥合了解剖评估和功能结果之间的差距。未来机器学习和预测分析的整合可以完善风险分层，实现量身定制的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Technology and Health Care HEALTH CARE SCIENCES & SERVICES-ENGINEERING, BIOMEDICAL

CiteScore

2.10

自引率

6.20%

发文量

282

审稿时长

>12 weeks

期刊介绍： Technology and Health Care is intended to serve as a forum for the presentation of original articles and technical notes, observing rigorous scientific standards. Furthermore, upon invitation, reviews, tutorials, discussion papers and minisymposia are featured. The main focus of THC is related to the overlapping areas of engineering and medicine. The following types of contributions are considered: 1.Original articles: New concepts, procedures and devices associated with the use of technology in medical research and clinical practice are presented to a readership with a widespread background in engineering and/or medicine. In particular, the clinical benefit deriving from the application of engineering methods and devices in clinical medicine should be demonstrated. Typically, full length original contributions have a length of 4000 words, thereby taking duly into account figures and tables. 2.Technical Notes and Short Communications: Technical Notes relate to novel technical developments with relevance for clinical medicine. In Short Communications, clinical applications are shortly described. 3.Both Technical Notes and Short Communications typically have a length of 1500 words. Reviews and Tutorials (upon invitation only): Tutorial and educational articles for persons with a primarily medical background on principles of engineering with particular significance for biomedical applications and vice versa are presented. The Editorial Board is responsible for the selection of topics. 4.Minisymposia (upon invitation only): Under the leadership of a Special Editor, controversial or important issues relating to health care are highlighted and discussed by various authors. 5.Letters to the Editors: Discussions or short statements (not indexed).